In Memoriam: Robert “Bob” S. Sherwin, MD
Robert “Bob” S. Sherwin, MD, the inaugural director of YCCI, passed away on March 31 at Yale-New Haven Hospital after a long illness. He was 80 years old. Dr. Sherwin, a world-renowned academic diabetologist, led YCCI through a remarkable period of growth, and all of those who worked with him will remember his kindness, guidance, and wisdom. Together they mourn the loss of a leader whose inspiring vision will continue to serve as a beacon for the growth of clinical and translation research at Yale, and beyond, for years to come.
WHRY Launches Studies on Endometrial Cancer, Addiction to Opioids, and Stroke
While continuing to focus on the impacts of COVID-19, the center has enlarged its research portfolio to include new projects on the prevention of endometrial cancer in a growing cohort of women at high risk, non-opioid pain management following a cesarean section for women with opioid use disorder who are in recovery, and sex differences in stroke.
Leptin hormone spurs body’s shift from burning carbs to fat
To keep the human brain supplied with energy when food was scarce, mammals evolved the ability to switch from burning carbohydrates to burning fat in order to preserve skeletal muscle that would otherwise be metabolized and converted to glucose. Scientists have long believed that the transition to fat metabolism was instigated solely by a drop in insulin. But a new study has identified leptin — a hormone made by fat cells — as a key mediator in this fundamental biological process.
Introducing the Internal Medicine 2021-2022 Annual Report
In the new report, there are updates from our clinical programs, research endeavors, our work on diversity, equity, and inclusion, and educational programs. Our faculty members were honored for their educational excellence. Research initiatives at Yale received applause on the national and international stages. This book highlights all that we have accomplished together this past year…
3 Factors Keeping Americans From New Weight-Loss Drugs
The shifts in attitude about obesity can also be seen in the KFF survey, said Dr. Ania Jastreboff, an endocrinologist and obesity-medicine specialist at Yale University and a consultant for the makers of the new drugs. After decades of hearing that losing weight was just a matter of exerting willpower, most of the public is intensely interested in medical treatments.Source: The New York Times
Yale’s Endocrine Neoplasia Program Is Flourishing
The Yale Multidisciplinary Endocrine Neoplasia Clinic has been treating benign and malignant diseases of the thyroid, parathyroid, adrenal, and pituitary glands since 2013. The program is a collaboration between the Department of Internal Medicine’s Section of Endocrinology & Metabolism and Yale Cancer Center and Smilow Cancer Hospital.
Are Ozempic and Wegovy Safe? All About the Diabetes and Obesity Drugs
PEOPLE spoke with Ania Jastreboff M.D., PhD., an obesity medicine physician scientist at Yale University to better understand the drugs and correct common misconceptions about obesity By Sheila Cosgrove Baylis Published on January 24, 2023 02:28 PMSource: People
DELIVER: Dapagliflozin cuts risk for worsening HF in adults with, without type 2 diabetes
Dapagliflozin reduces risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial.Source: Healio
High liver fat associated with impaired glucose, type 2 diabetes in pediatric obesity
Children with obesity and a high level of liver fat content are more likely to have impaired glucose tolerance, prediabetes and type 2 diabetes compared with those with normal liver fat content, according to Sonia Caprio, MD.Source: Healio